Have a feature idea you'd love to see implemented?
Let us know!
DSGN Design Therapeutics Inc
Price (delayed)
$5.35
Market cap
$302.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.9
Enterprise value
$259.17M
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on
Highlights
The quick ratio has soared by 63% YoY and by 7% from the previous quarter
The EPS rose by 33% year-on-year and by 14% since the previous quarter
Design Therapeutics's equity has decreased by 12% YoY and by 3.1% QoQ
Key stats
What are the main financial stats of DSGN
Market
Valuations
Earnings
Shares outstanding
56.62M
Market cap
$302.92M
Enterprise value
$259.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$50.53M
EBITDA
-$49.94M
Free cash flow
-$51.47M
Per share
Balance sheet
Liquidity
EPS
-$0.9
Free cash flow per share
-$0.91
Book value per share
$4.62
Revenue per share
$0
TBVPS
$4.77
Total assets
$269.58M
Total liabilities
$8.34M
Debt
$1.95M
Equity
$261.24M
Working capital
$258.45M
Debt to equity
0.01
Current ratio
41.42
Quick ratio
40.82
Net debt/EBITDA
0.88
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-17.8%
Return on equity
-18.5%
Return on invested capital
-20.5%
Return on capital employed
-19.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DSGN stock price
How has the Design Therapeutics stock price performed over time
Intraday
-5.48%
1 week
-11.13%
1 month
-1.11%
1 year
155.98%
YTD
101.89%
QTD
-0.56%
Financial performance
How have Design Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.39M
Net income
-$50.53M
Gross margin
N/A
Net margin
N/A
DSGN's net income is up by 32% YoY and by 14% QoQ
DSGN's operating income is up by 23% year-on-year and by 11% since the previous quarter
Growth
What is Design Therapeutics's growth rate over time
Valuation
What is Design Therapeutics stock price valuation
P/E
N/A
P/B
1.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 33% year-on-year and by 14% since the previous quarter
DSGN's P/B is 93% above its last 4 quarters average of 0.6
Design Therapeutics's equity has decreased by 12% YoY and by 3.1% QoQ
Efficiency
How efficient is Design Therapeutics business performance
DSGN's ROE is up by 20% YoY and by 11% QoQ
Design Therapeutics's ROA has increased by 20% YoY and by 11% from the previous quarter
The company's return on invested capital rose by 19% YoY and by 9% QoQ
Dividends
What is DSGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DSGN.
Financial health
How did Design Therapeutics financials performed over time
DSGN's current ratio has surged by 64% year-on-year and by 7% since the previous quarter
The quick ratio has soared by 63% YoY and by 7% from the previous quarter
DSGN's debt is 99% smaller than its equity
DSGN's debt is down by 28% year-on-year and by 9% since the previous quarter
Design Therapeutics's equity has decreased by 12% YoY and by 3.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.